FATE - CIK 0001434316
FATE THERAPEUTICS INC trades as FATE. In its fiscal 2025 annual report the company posted revenue of $6.65M, down 51.2% from the prior year and net income of -$136.31M. This page tracks FATE THERAPEUTICS INC through 827 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years FATE THERAPEUTICS INC's revenue grew from $4.40M to $6.65M, a compound annual growth rate of 4.7%. Net profit margin compressed from -760.2% to -2051.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Insider trade | 4 | 2026-05-07 |
| Insider trade | 4 | 2026-05-06 |
The largest companies sharing FATE THERAPEUTICS INC's SEC industry classification (biological products, (no diagnostic substances)).
FATE THERAPEUTICS INC reported revenue of $6.65M for fiscal year 2025, a decrease of 51.2% year over year.
In its latest fiscal year FATE THERAPEUTICS INC reported a net loss of $136.31M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.